Abstract
Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis. This article discusses pimavanserin's mechanism of action, which patients are appropriate candidates for therapy, adverse reactions, and appropriate dosing.
MeSH terms
-
Antipsychotic Agents
-
Humans
-
Parkinson Disease / complications*
-
Piperidines / administration & dosage*
-
Piperidines / adverse effects
-
Piperidines / pharmacology
-
Psychotic Disorders / drug therapy*
-
Psychotic Disorders / etiology*
-
Serotonin 5-HT2 Receptor Antagonists*
-
Urea / administration & dosage
-
Urea / adverse effects
-
Urea / analogs & derivatives*
-
Urea / pharmacology
Substances
-
Antipsychotic Agents
-
Piperidines
-
Serotonin 5-HT2 Receptor Antagonists
-
Urea
-
pimavanserin